Meet & Greet the ONCOLOGY Board Members and Editorial Team at ASH 2018

Article
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

The ONCOLOGY team invites you to attend a meet and greet event with our team and members of our expert Advisory Board at the 60th American Society of Hematology (ASH) 2018 meeting in San Diego, California. Appetizers and drinks will be served!

Meet the following hematology/oncology experts:

  • Julie M. Vose, MD, MBA, FACP, FASCO
  • John Sweetenham, MD, FRCP
  • Stephen T. Rosen, MD

Event Details

Date: Saturday, December 1, 2018

Time: 2:00 PM to 3:00 PM

Location: Booth #3011 in the San Diego Convention Center Exhibit Hall
 

Recent Videos
Marc S. Raab, MD, PhD, details how agents like carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
Related Content
In patients with ES-ECLC treated with chemotherapy and immunotherapy, stereotactic body radiation therapy did not significantly improve overall survival.

Thoracic Consolidation Plus SBRT to Cranial Mets May Improve OS in ES-SCLC

Roman Fabbricatore
September 24th 2025
Article

In patients with ES-ECLC treated with chemotherapy and immunotherapy, stereotactic body radiation therapy did not significantly improve overall survival.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Cytokine release syndrome occurred in 36.1% of patients, with 22.2% being grade 1 and 13.9% being grade 2.

Is There Space for Single-Agent Mosunetuzumab in Frontline MZL Care?

Tim Cortese
September 22nd 2025
Article

Results from the phase 2 MorningSun trial demonstrated that outpatient, subcutaneous single-agent mosunetuzumab was efficacious in patients with marginal zone lymphoma.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

The investigators noted no new safety signals were reported in this trial.

Isa-VRd Meets Primary End Point in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Ariana Pelosci
September 20th 2025
Article

The VGPR or better rate was 87.8% in patients treated with Isa-VRd who had transplant-ineligible newly diagnosed multiple myeloma.

No TRAEs leading to dose discontinuation, DLTs, or belantamab-related corneal events above grade 1 occurred with belantamab in multiple myeloma.

Belantamab Exhibits Rapid/Prolonged Plasmablast Cell Reduction in Myeloma

Roman Fabbricatore
September 20th 2025
Article

No TRAEs leading to dose discontinuation, DLTs, or belantamab-related corneal events above grade 1 occurred with belantamab in multiple myeloma.